Certara (CERT) strong mid-cap name today that has held up well recently as it consolidates the strong run higher from August. Shares are forming a small base above the 55-EMA and today back above its 8- and 21-day with room above monthly VPOC at $35.75 to recent highs near $40 and a bigger measured move to $50. Shares are hitting the ‘ready to run’ scan mid-day with both RSI and MACD showing signs of turning the corner after pulling back from overbought conditions. The $5B company focuses on software and services for the biotech and healthcare industry through biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. The company has a lot of room for growth as they are currently working with roughly 25% of the market, and there are as many as 3,000 companies that could benefit from incorporating biosimulation into their workflows.